Hepatology

Dapagliflozin shows promise for treating MASH, improving liver outcomes without worsening fibrosis in a major trial.

A 2023 global call to action by over 300 experts highlighted the need for clear, cross-specialty care pathways to support earlier identification and referral of people at risk.

In this double-blind, placebo-controlled trial, 181 participants were randomised to receive weekly injections of either 28 mg or 50 mg of efruxifermin or a placebo.

These figures indicate a substantial drop-off following diagnosis, undermining efforts to eliminate HCV in paediatric populations.

The model analyses demographic information, lab results, and other clinical data to predict the cause of graft injury across six possible conditions.

This new study highlights the growing role of extracellular volume measurement using spectral CT, which quantifies the proportion of extracellular matrix.

The findings support the concept that excessive lipogenesis, rather than just fat delivery from other sources, is central to MASLD development.

A study has revealed that pemafibrate is more effective than omega-3 fatty acid ethyl in reducing fatty liver index.